Gemtuzumab ozogamicin with fludarabine,cytarabine, and granulocyte colony stimulating factor (FLAG‐GO) as front‐line regimen in patients with core binding factor acute myelogenous leukemia |
| |
| Authors: | Gautam Borthakur Jorge E Cortes Elihu E Estey Elias Jabbour Stefan Faderl Susan O'Brien Guillermo Garcia‐Manero Tapan Mahendra Kadia Xuemei Wang Keyur Patel Rajyalakshmi Luthra Charles Koller Mark Brandt Farhad Ravandi Hagop Kantarjian |
| |
| Institution: | 1. Department of Leukemia, MD Anderson Cancer Center, Houston, Texas;2. Division of Hematology, University of Washington School of Medicine, Seattle, Washington;3. Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas;4. Department of Hematopathology, MD Anderson Cancer Center, Houston, Texas |
| |
| Abstract: | Despite being considered “good‐risk” acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG‐GO) as front‐line therapy of patients with CBF AML. Forty‐five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG‐GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML. Am. J. Hematol. 89:964–968, 2014. © 2014 Wiley Periodicals, Inc. |
| |
| Keywords: | |
|
|
